Medivation Plans “Aggressive” Timeline For Alzheimer’s, Huntington’s NDAs
This article was originally published in The Pink Sheet Daily
Dimebon safety profile compares favorably to Aricept, Exelon and Razadyne, CEO says.
You may also be interested in...
Biomarkers and diagnostic tools must be developed to allow drug manufacturers to target Alzheimer’s disease modification, BioInvestor Forum panelists say.
Huntington's disease treatment tetrabenazine received an FDA "approvable" letter March 24.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.